, Tracking Stock Market Picks
Enter Symbol:

up 73.09 %

MEDIVATION INC (MDVN) rated Buy with price target $125 by Aegis Capital

Posted on: Wednesday,  Jan 29, 2014  9:25 AM ET by Aegis Capital

Aegis Capital rated Buy MEDIVATION INC (NASDAQ: MDVN) on 01/29/2014. Previously Aegis Capital rated Buy MEDIVATION INC (NASDAQ: MDVN) on 09/25/2012.,
when the stock price was $53.19. Since then, MEDIVATION INC has gained 73.10% as of 01/27/2016's recent price of $92.07.
If you would have followed the previous Aegis Capital's recommendation on MDVN, you would have gained 73.09% of your investment in 1219 days.

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three medical needs: Alzheimer?s disease, Huntington?s disease and castration-resistant prostate cancer. The Company has formed separate subsidiaries to hold the product candidates it is developing. The Company?s subsidiary Medivation Neurology, Inc. holds its Dimebon technology, and its subsidiary Medivation Prostate Therapeutics, Inc. holds its MDV300 series technology.

Aegis Capital
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/29/2014 9:25 AM Buy
83.90 125.00
as of 10/17/2014
1 Week up  1.36 %
1 Month down  -3.76 %
3 Months up  35.48 %
1 YTD up  47.71 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/15/2012 12:25 PM Buy
43.77 100.00
9/25/2012 8:25 AM Buy
53.19 90.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy